Author

J. Erickson

Observed names: Erickson, J, J Erickson, Janelle Erickson, Janelle S Erickson, Janelle S. Erickson, Janelle Shannon Erickson

Institution: Eli Lilly (United States)

Observed institutions: Northwestern University, Dalhousie University, Harvard University, Jichi Medical University, Baylor University, Eli Lilly (United States), Virginia Commonwealth University, University of Münster, McLean Hospital, Karolinska Institutet, Bristol-Myers Squibb (United States), The Gordon Hospital, Probity Medical Research, Oregon Medical Research Center, Stanford Medicine, New York State Psychiatric Institute, Orexigen Therapeutics (United States), Columbia University

OpenAlex ID: A5083162003

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

2010 · Frank L Greenway, Ken Fujioka, et al. · The Lancet · 1,033

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

2016 · Kenneth B. Gordon, Andrew Blauvelt, et al. · New England Journal of Medicine · 851

PDF

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

2015 · Christopher E M Griffiths, Kristian Reich, et al. · The Lancet · 835

Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial

2010 · Thomas A. Wadden, John P. Foreyt, et al. · Obesity · 558

PDF

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

2007 · James Hartford, Susan Kornstein, et al. · International Clinical Psychopharmacology · 286

Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo

2009 · Frank L. Greenway, Eduardo Dunayevich, et al. · The Journal of Clinical Endocrinology & Metabolism · 180

PDF

Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder

2007 · Eduardo Dunayevich, Janelle Erickson, et al. · Neuropsychopharmacology · 179

Pain Assessment for the Dementing Elderly (PADE): Reliability and Validity of a New Measure

2003 · Michael R. Villanueva, Tricia L. Smith, et al. · Journal of the American Medical Directors Association · 156

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial

2007 · Moira Rynn, James Russell, et al. · Depression and Anxiety · 144

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

2014 · Kenneth B. Gordon, Craig L. Leonardi, et al. · Journal of the American Academy of Dermatology · 107

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)

2017 · K.A. Papp, C.L. Leonardi, et al. · British Journal of Dermatology · 96

PDF

Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of UNCOVER ‐3

2016 · P. van de Kerkhof, L. Guenther, et al. · Journal of the European Academy of Dermatology and Venereology · 83

Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial

2008 · Jonathan R.T. Davidson, Hans-Ulrich Wittchen, et al. · European Neuropsychopharmacology · 68

Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial

2008 · H. Nicolini, D. Bakish, et al. · Psychological Medicine · 66

An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects

2009 · Charles S. Wilcox, Nader Oskooilar, et al. · Addictive Behaviors · 61

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

2020 · Vinod Chandran, Désirée van der Heijde, et al. · Lara D. Veeken · 57

PDF

Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double‐blind, placebo‐controlled studies

2008 · Jonathan Davidson, Christer Allgulander, et al. · Human Psychopharmacology Clinical and Experimental · 57

Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies

2016 · A.B. Gottlieb, J.‐P. Lacour, et al. · Journal of the European Academy of Dermatology and Venereology · 56

PDF

Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis

2013 · B. Zhu, E. Edson-Heredia, et al. · British Journal of Dermatology · 47

Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials

2007 · Christer Allgulander, James Hartford, et al. · Current Medical Research and Opinion · 47

A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder

2008 · C Allgulander, D Nutt, et al. · Journal of Psychopharmacology · 43

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

2019 · L Guenther, A Bleakman, et al. · Acta Dermato Venereologica · 42

Duloxetine Treatment for Role Functioning Improvement in Generalized Anxiety Disorder

2007 · Jean Endicott, James M. Russell, et al. · The Journal of Clinical Psychiatry · 41

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis

2015 · Mark C. Genovese, Daniel K. Braun, et al. · The Journal of Rheumatology · 35

Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms

2007 · James M. Russell, Risa Weisberg, et al. · Depression and Anxiety · 35

Works count: 45

Citation count: 5,225

H-index: 25

I10-index: 26